24/7 Market News Snapshot 30 December, 2024 – Polyrizon Ltd. Ordinary Shares (NASDAQ:PLRZ)

December 30, 2024

DENVER, Colo., 30 December, 2024 (247marketnews.com) – (NASDAQ:PLRZ) are discussed in this article.
Polyrizon Ltd. is currently experiencing a significant surge in pre-market trading, with shares reaching $2.00, marking a notable 21.95% increase from the previous close of $1.64. Trading volume has also surged to 1.86 million shares, reflecting increased investor interest and market optimism. This momentum indicates a strong performance potential for the company, positioning Polyrizon as a stock to watch in the coming trading session.

Further bolstering investor confidence, Polyrizon recently announced a major milestone in the advancement of its nasal drug delivery and protection technologies. The United States Patent and Trademark Office (USPTO) has published a national phase patent application that outlines critical elements of the company’s two innovative platforms: Capture and Contain (C&C™) and Trap and Target (T&T™).

The C&C™ platform leverages a specially engineered 3D polymeric network to establish a protective barrier within the nasal mucosa, effectively capturing airborne biological threats such as allergens and viruses. This natural hydrogel technology functions as a ‘biological mask’ in the nasal cavity, enhancing the body’s defenses against health risks. In conjunction, the T&T™ platform focuses on optimizing drug delivery through extended residence time within the nasal cavity, facilitating more efficient and targeted medication administration across various medical applications.

As a progressive development-stage biotech company, Polyrizon remains dedicated to integrating innovative science with practical healthcare solutions. Their commitment to redefining standards of care in nasal drug delivery is underscored by the recent patent publication, showcasing their relentless pursuit of advancing patient care and enhancing protection against airborne threats. With these developments, Polyrizon is well-positioned to potentially transform the biopharmaceutical landscape.

Related news for (PLRZ)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.